Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00083707
Status:
COMPLETED
Last Update Posted:
2010-07-05
First Post:
2004-05-27
Brief Title:
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstroms Macroglobulinemia
Sponsor:
University of Arkansas
Organization:
University of Arkansas
Study Overview
Official Title:
UARK 99-006 A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstroms Macroglobulinemia
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research is to study how helpful thalidomide is in controlling the disease and to study any side effects from taking thalidomide
Detailed Description:
Patients will receive thalidomide in the oral form each night before bed The dose of thalidomide will be increased each week until week 7 as long as there are no significant side effects
Routine physical examinations and blood tests will be done to monitor the effect of treatment and the toxicities encountered if any and provide the available treatments for side effects accordingly Blood tests will be done to monitor the tumor response
Routine physical examinations and blood tests will be done to monitor the effect of treatment and the toxicities encountered if any and provide the available treatments for side effects accordingly Blood tests will be done to monitor the tumor response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None